Executive Summary
The European Heart Journal's "Great Debate" on SAVR-first for patients with life expectancy beyond 5 years lands the same week ESC/EACTS guidelines push TAVI to age 70+ — surgeons are pushing back hard, citing pacemaker burden, paravalvular leak, and the durability vacuum past 5 years. SwissTAVI registry data on 19,452 patients show 1-year MACE collapsing from 16% to 9.1% across 2011-2024 even as volumes grew 27% annually, and a TriNetX cohort of 966 matched patients reported a 41% mortality reduction at 1 year with tricuspid TEER versus medical therapy. CMS reopened the TAVR National Coverage Analysis (CAG-00430R2) for public comment, which complicates the coverage calculus just as the SAVR-first camp gets a louder microphone.
- EHJ "Great Debate" challenges the ESC 2025 age-70 TAVI threshold, citing inadequate >5-year durability data and pacemaker/PVL burden (EHJ).
- SwissTAVI registry: 30-day MACE dropped from 6.9% to 4.0% and procedural mortality fell from 2.9% to 1.2% across three eras, with risk-adjusted gains exceeding lower-risk casemix alone (Cardiovasc Interv Ther).
- PRIME-MR registry (n=3,082) shows M-TEER for primary MR complications halved (42% to 23%) and residual MR ≤1+ rose to 68% in the 2020-2023 era (EuroIntervention).
- Tricuspid TEER meta-analysis (n=4,134): 1-year mortality 14%, HF rehospitalization 17%, and 31% remain NYHA III-IV despite TR reduction (Ann Cardiothorac Surg).
- CMS opened TAVR National Coverage Analysis (CAG-00430R2) for public comment, signaling potential reimbursement framework changes (CMS).
What to watch: The CMS public comment window on CAG-00430R2 will set the tone for whether US coverage policy follows the ESC's age-70 pivot or anchors to the surgical counterargument.
Aortic Valve (TAVR/TAVI)
Real-world TAVI outcomes keep improving while the surgical community formally questions whether the science has earned the ESC's age-70 threshold. [NOTABLE] Doenst, Prendergast, Allen, Barili, Falk and colleagues' EHJ "Great Debate" argues SAVR should remain first choice when life expectancy exceeds 5 years — citing the absence of robust >5-year RCT data, persistently higher pacemaker and PVL rates with TAVI, and conflicting real-world registries. This sits directly against ESC/EACTS 2025 (Class I TAVI ≥70 with tricuspid anatomy and TF access) and ACC/AHA 2020 (SAVR preferred <65). The 65-70 age band remains the most contested real estate in structural heart.
The SwissTAVI registry (n=19,452, prospective nationwide, observational) gives the TAVI camp ammunition: adjusted 1-year MACE HR 0.69 across three eras despite 27% annual volume growth, with median STS dropping from 4.5% to 3.3%. The longest follow-up remains bounded by what the field knows at 5 years — the structural valve deterioration story beyond that horizon is where TAVI remains most exposed. ACC/AHA 2020 anchors SAVR preference below age 65 precisely on this durability ground; ESC 2025 moved that threshold to 70, a shift the EHJ debate authors argue the evidence does not yet support. A speckle-tracking comparison (n=373, single-center) showed RV function deteriorated post-SAVR versus TAVI at 1 year, with LAVI and LV-GLS independently predicting mortality and AF — one more point for transcatheter when RV preservation matters, though small-sample observational data cannot settle the question. CMS's reopened TAVR NCA CAG-00430R2 will arbitrate this debate in the US market.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER outcomes for primary MR are improving with each device generation, but the benchmark keeps moving. [NOTABLE] The PRIME-MR registry (n=3,082, 27 centers) showed procedures-with-complications fell from 42.4% (2009-2013) to 23.1% (2020-2023), residual MR ≤1+ rose from 54.0% to 68.4%, and stable 1-year results climbed to 74.4%. ACC/AHA 2020 and ESC 2025 both position TEER as Class IIa for high-risk symptomatic primary MR — surgical repair remains Class I when a durable result is expected, and ESC 2025's upgrade to Class I for early asymptomatic repair (with 3+ risk factors: AF, SPAP >50 mmHg, LA dilation, or concomitant TR ≥moderate) keeps surgery the primary play in operable patients. PRIME-MR's improving results sharpen the argument for TEER only in those who genuinely cannot tolerate surgery.
The OCEAN-Mitral haemodynamic substudy (n=2,629, registry-based) found mLAP reduction during M-TEER independently predicted lower mortality/HF rehospitalization in degenerative MR (adjusted HR 0.66) but not functional MR — interaction p=0.006. Intraprocedural hemodynamics sharpen patient selection beyond MR grade alone, though registry data cannot establish causality. A separate OCEAN/REVEAL-AFMR propensity analysis showed TEER for atrial functional MR cut death/HF hospitalization (HR 0.65) versus medical therapy — relevant given ESC 2025's new atrial SMR entity, where formal pathways favor surgery plus LAAO (Class IIa) with TEER reserved for inoperable cases (Class IIb). Propensity matching does not substitute for randomization in this population.
Tricuspid Valve (TriClip, TTVR)
Tricuspid is where the field's enthusiasm most clearly outpaces hard mortality evidence. [NOTABLE] The TriNetX T-TEER cohort (n=483 matched pairs) reported 1-year mortality HR 0.59 versus medical therapy, sustained to 5 years (HR 0.68) — but this is retrospective, propensity-matched real-world data, not an RCT. The contemporary meta-analysis of 4,134 T-TEER patients across 10 studies shows pooled 1-year mortality of 14.0%, HF rehospitalization 16.9%, and 30.9% still NYHA III-IV — TR reduction does not equal symptom resolution in roughly a third of patients. ESC 2025 elevated transcatheter TR therapy to Class IIa LOE A on the strength of TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 was silent on the category entirely. Surgery guided by TRI-SCORE-based patient selection still owns the lower-risk space, and the ESC 2025 upgraded isolated TV surgery for symptomatic severe primary TR to Class I — Patil et al. argue isolated TV surgery and transcatheter approaches address distinct populations, not competitors.
The Leipzig 30-year experience (n=982) reinforces this point: 1-year survival was 88% surgical, 83% T-TEER, 94% TTVR — but surgical patients were 12-14 years younger with fewer comorbidities, making cross-modality comparison unreliable. Surgical TV repair beat replacement at 9 years (65% vs 55% survival), and reoperations matched primary procedures (55% vs 59%) — durability the transcatheter space cannot yet claim. The TRI-SCORE validation in 60 TTVI patients outperformed MELD-XI, EuroSCORE II, GLIDE, and TRIVALVE for predicting 12-month mortality (AUC 0.76) — the disease-specific score the ESC 2025 algorithm anchors to, though validation in 60 patients demands cautious extrapolation.
Surgical vs. Transcatheter Comparisons
Transcatheter and surgical therapies are serving different populations, not competing for the same patient. The EHJ "Great Debate" formalizes the SAVR-first position for >5-year life expectancy. The Leipzig three-decade tricuspid series makes the same point empirically — surgical TV repair beat replacement (9-year survival 65% vs 55%), and reoperations matched primary procedures (55% vs 59%), evidence that surgical durability the transcatheter space cannot yet match remains a real clinical differentiator, not a rhetorical one.
Preprint Highlights
A BioVU/All of Us biobank analysis (n=545,926) found 2.6% and 1.5% of patients with primary conduction disorders carried P/LP variants in cardiomyopathy genes, with carrier status linked to higher HF incidence and >2-fold increased third-degree AVB risk after HF diagnosis. Post-TAVI conduction disturbance attribution may be more complex than purely procedural — genetic substrate may matter, particularly in younger patients now entering the TAVI cohort as the ESC 2025 age-70 threshold expands the eligible population.
Device & Technology
A bench-test comparison of the Edwards SAPIEN 3 (23 mm) versus Meril MyVal OCTACOR (21.5 mm) showed both tolerate stepwise dilation to nominal size, with SAPIEN 3 remaining functional at +13% overexpansion and OCTACOR tolerating +20.9% before leaflet tears — relevant for pediatric pulmonary/mitral applications. The VeriSight Pro 3D ICE catheter (n=45, single-center) reduced fluoroscopy time (16 vs 26 min) and radiation dose by ~45% during tricuspid TEER, without compromising safety. Selective metal cell excision during open TAVR explant was reported as a feasible technique to preserve LMCA access — relevant given the rising redo-TAVR question and evidence that THV explantation carries 12-17% mortality.
Regulatory & Policy
CMS reopened the TAVR National Coverage Analysis CAG-00430R2 for public comment. The previous NCD anchored hospital and operator volume requirements that have shaped US TAVR distribution. With ESC 2025 pushing TAVI down to age 70 and the EHJ surgical pushback intensifying, this NCA review will determine whether US reimbursement aligns with European indication expansion or holds the line at the ACC/AHA 2020 framework. Abbott initiated a recall of heart monitoring technology (covered by Cardiovascular Business) — adding to ABT's stretch of regulatory friction.
Industry & Market
Anteris Technologies used a PR Newswire briefing to reframe the TAVR durability question around longer-living patients, paralleled by MassDevice coverage — the company is positioning DurAVR as the lifetime-management answer the field has been asking for. Edwards continues to lean on the SAPIEN 3 Ultra Resilia narrative for tissue durability claims as the low-risk indication expands.
Financial Analysis
The valve sector's underlying clinical narrative — durability scrutiny on TAVI, tricuspid TEER mortality data still soft despite TR reduction, and a CMS reimbursement review — sits awkwardly against weak share-price action across the large-cap names. BSX has lost roughly half its value over six months, ABT is down ~30%, and MDT down ~17%. Only Anteris (AVR.AX) is up — nearly doubling on a thesis the durability gap will be its market. Edwards has held best among the legacy structural names, helped by the Sapien 3 Ultra Resilia narrative and the EARLY TAVR tailwind. The Doenst EHJ debate plus CMS NCA reopen could swing sentiment on EW/MDT/ABT structural divisions over the next quarter.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $85.11 | 6-month range $74.66–$89.48 | Market cap $49.7B
- P/E (trailing) 46.64 | Forward P/E 25.62 | Beta 0.87
- Analyst target $96.92 (26 analysts), consensus Buy — implied upside ~14%
- Next earnings 2026-07-23, EPS est $0.74, revenue est $1.70B
- EW has held best of the legacy names through the TAVR durability debate, supported by the SAPIEN 3 Ultra Resilia tissue durability narrative and EARLY TAVR's asymptomatic indication tailwind.
Medtronic (MDT)
- Close: $80.20 | 6-month range $73.31–$104.65 | Market cap $103.2B
- P/E (trailing) 21.55 | Forward P/E 12.55 | Beta 0.60
- Analyst target $98.00 (26 analysts), consensus Buy — implied upside ~22%
- Next earnings 2026-08-18, EPS est $1.39, revenue est $9.55B
- MDT is most exposed to the SAVR-first EHJ debate — Evolut volumes will be sensitive to whether the 65-75 age band tilts back toward surgery and to the CMS NCA outcome.